About the Lauffer Lab

We work in the field of interventional genetics, developing new therapeutic strategies alongside computational tools and translational frameworks that help identify the most suitable therapeutic option for any given target.

The Lauffer Lab combines wet-lab and computational approaches to advance therapeutic discovery and translation. Our work aims to build a genuinely multidisciplinary research environment that bridges clinical expertise, experimental research, and computational analysis. We collaborate closely with clinicians, genetic counsellors, ethicists, and psychologists to ensure that scientific advances are developed responsibly and with careful consideration of the broader clinical and societal context.

Patient and public engagement is a central component of our work. We believe that the development of new genomic therapies must be informed by the experiences, perspectives, and priorities of patients and families affected by rare disease.

Our work focuses on three core aims:

• Expanding the genetic therapy toolbox by developing new therapeutic strategies to target rare genetic disorders.
• Developing computational tools to accelerate target identification and prioritisation of cases for genetic therapy development.
• Standardising therapeutic amenability assessments and translating them into practical resources for clinicians and patients, including frameworks, guidelines, and actionability reports that support decision-making around genetic therapies.

The Lauffer Lab contributes to several (inter)national collaborations that aim to integrate emerging genetic therapies into routine medical practice. These include the MRC Centre of Research Excellence (CoRE) in Therapeutic Genomics and the N=1 Collaborative , a global initiative working to standardise, optimise and streamline individualised genetic therapy development.